<DOC>
	<DOCNO>NCT01623752</DOCNO>
	<brief_summary>It know COMET-trial patient start Enbrel treatment early great chance reach clinical remission radiographic nonprogression . It still unclear , however , many patient early arthritis achieve remission radiographic nonprogression condition routine rheumatologic care local recommendation Enbrel treatment ( pre-treatment least 2 DMARDs , one MTX ) . Therefore , robust x-ray data available show/demonstrate - average extent x-ray damage routine patient Enbrel outside clinical study . - outstanding effect structural damage Enbrel reproduce routine practice . - 'Silent Progressor ' issue relevant clinical trial , also day-to-day decision making . - optimal onset Enbrel treatment course disease prevent radiographic damage</brief_summary>
	<brief_title>Prospective Evaluation Radiographic Efficacy Enbrel</brief_title>
	<detailed_description>Non-interventional study : subject select accord usual clinical practice physician</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subject eligibility review document appropriately qualified member investigator 's study team subject include study . Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect study requirement inclusion study . Subjects must meet follow inclusion criterion eligible enrollment study : Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Definitive diagnosis RA PsA . Eligible Etanercept treatment accord Summary Product Characteristics ( SmPC ) . Inclusion subject pretreated biologics Etanercept possible One plain radiograph hand foot ( Anteroposterior ) within 3 month prior initiation treatment Etanercept one plan consecutive radiograph hand foot take 12 18 month accord German recommendation patient treat biologics . Receipt investigational drug within 3 month study inclusion . Exclusion Criteria accord EnbrelÂ® SmPC , particular attention : Hypersensitivity active substance ( etanercept ) excipients . Sepsis risk sepsis . Active infection , include chronic localise infection . Subjects receive previous treatment etanercept Subjects investigational site staff member subject Pfizer employee directly involve conduct trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>